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Abstract 
Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound 
added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer 
(mCRPC) who progressed to docetaxel. The anti-tumour activity and safety of enzalutamide has been 
demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary 
endpoint. There are no head-to-head studies comparing the different treatment options in this subset of 
patients. In this article, most relevant data published in the literature have been reviewed, with special 
attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasising 
the mechanisms of action of the different drugs, efficacy and quality of life-related aspects. 
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Introduction 
Docetaxel combined with prednisone is currently the treatment of choice in patients with 
disseminated castration-resistant prostate cancer (CRPC). The option of docetaxel plus prednisone 
in advanced CRPC was approved in 2004 after publication of two independent phase III 
randomised studies showing an improvement in overall survival and quality of life in this group of 
patients [1], [2]. Thereafter, a better knowledge of the mechanisms of resistance and androgen 
production-related signalling pathways made possible the synthesis of new drugs with different 
mechanisms of action, including chemotherapeutic agents (cabazitaxel) [3] and agents with anti-
androgenic activity (abiraterone acetate and enzalutamide) [4], [5], [6], all of which have 
demonstrated an increase in survival after disease progression on docetaxel. 
 
This article presents a review of the different mechanisms of action of these drugs, with a 
particular focus on enzalutamide (MDV3100) because of its pharmacological characteristics, 
toxicity profile and health-related quality of life benefits in patients with prostate adenocarcinoma 
who had been treated with docetaxel. 
Comparative analysis of the mechanisms of action 
The development of CRPC is characterised by progression of the disease despite serum 
testosterone levels in the range of castration. There is increasing evidence of CRPC dependence on 
the androgen-receptor (AR) signalling pathway and underlying mechanisms. Androgen receptor 
expression is maintained throughout prostate cancer progression. Adrenal and intra-tumour 
androgens are an important source of AR activation. Other mechanisms resulting in permanent 
activation of AR include amplification and overexpression of the AR gene, AR mutations reducing 
ligand-binding specificity, activation of alternative Ras/Raf/MEK/ERK or Src and Ack1 thyrosine 
kinase pathways, altered levels of proteins promoting co-activation of AR and constitutively active 
AR splice variants [7]. 
 
The taxanes are microtubule-stabilising agents. Microtubules, key components of the 
cytoskeleton, are crucial in the development and maintenance of cell shape, in the transport of 
vesicles, traffic of transcription factors, mitochondrial function, cell signalling and cell division 
and mitosis. Taxanes are known to have a role in the separation of chromosomes during mitosis 
preventing transition from metaphase to anaphase and promoting apoptosis [8], [9]. Also, taxanes 
inhibit anti-apoptotic function of the Bcl-2 family proteins [9], [10] and activate cyclin-dependent 
kinase inhibitor 1A (p21, Cip1) and p53 protein in cancer cells causing cell cycle arrest and 
apoptotic cell death [11]. Taxanes may also have a direct effect on androgenic signalling pathway 
in prostate cancer. The microtubule stabilising activity of taxanes leads to AR cytoplasmic 
sequestration and subsequent inhibition of transcription activity in response to androgens or other 
ligand-independent pathways [12], [13]. In addition, it has been shown that taxanes induce nuclear 
accumulation of FOXO1, which is a known AR suppressive nuclear factor [14]. It is possible that 
taxane inhibition of the AR signalling pathway may be more relevant than the anti-mitotic activity, 
which may explain why taxanes are the only chemotherapeutic agents with a beneficial effect on 
survival in prostate cancer. Cabazitaxel overcomes one of the mechanisms of resistance of other 
taxanes due to poor affinity for the p-glycoprotein drug efflux pump, a major mechanism of 
resistance to docetaxel [12]. 
 
Abiraterone, the active metabolite of abiraterone acetate, is an irreversible inhibitor of 
CYP17A1 [15], the 17α-hydroxilase and C17,20-lyase enzymatic activity of which is essential for 
androgen biosynthesis [16]. Pregnenolone and progesterone are converted to 17α-
hydroxipregnenolone and 17α-hydroxiprogesterone by the 17α-hydroxilase activity of CYP17A1, 
and then to dehydroepiandrosterone (DHEA) and androstenodione by C17,20-lyase activity. DHEA 
and androstenodione are precursors of testosterone [16]. CYP17A1 is expressed in testicular, 
adrenal and prostate tumour tissue. The expression of CYP17A1 in castration-resistant metastases 
has been reported to be 16.9 times higher than in the primary tumour [17]. Abiraterone requires the 
concurrent use of low-dose corticosteroids to inhibit ACTH stimulation and subsequent increase of 
mineralocorticoids and prevent secondary effects, such as fluid retention, hypokalemia and 
hypertension. 
 
Enzalutamide has a much higher affinity for the AR receptor than first-generation 
antiandrogens [7], with no agonist activity and demonstrates activity even in case of amplification 
and overexpression of the AR, which are well known mechanisms involved in androgenic 
castration resistance [18]. Enzalutamide inhibits the AR signalling pathway and is a competitor 
inhibitor of dihydrotestosterone (DHT), the active metabolite of testosterone. In contrast to first-
generation antiandrogens, enzalutamide also inhibits nuclear translocation of DHT-AR complex, 
remaining a significant fraction of AR in the cytoplasm and interfering directly in AR-mediated 
DNA transcription [18]. This clear differentiating mechanism results in a reduction of prostate 
cancer cell proliferation and an increase in cell death. Enzalutamide has also shown activity in AR 
splice variants lacking the ligand binding domain, a further known mechanism of castrate 
resistance, although detection of AR-V7 in circulating tumour cells may be associated with 
resistance to enzalutamide and abiraterone [19]. Therefore, in contrast to the ligand-dependent 
activity of abiraterone (adrenal and intratumoral residual androgens) in CRPC, enzalutamide acts 
on ligand-dependent resistance mechanisms (AR amplification) as well as ligand-independent 
resistance mechanisms (AR splice variants) (Fig. 1). 
 
 
 
Fig. 1. Mechanism of action of enzalutamide (ARB: androgen receptor binding). 
Unlike abiraterone, concomitant steroids are not needed because enzalutamide lacks the 
detrimental effects of mineralocorticoids excess. 
  
Despite the different mechanisms of action of enzalutamide and abiraterone, there is some 
scientific evidence of a possible interaction between taxanes and hormonal therapy based on 
preclinical data suggesting that androgen ablation, although effective in the control of the prostate 
tumour size, may increase the possibility of metastases and castration resistance by promoting 
epithelial mesenchymal transition (EMT) [20]. Androgen deprivation also increases ZEB1 
transcription factor levels, a direct regulator of EMT related to taxane resistance [21]. 
 
Clinical data mostly based on retrospective studies with a small number of patients also 
indicate that androgen-deprivation therapies may reduce the efficacy of subsequent treatments with 
taxanes [22], [23], [24]. Studies suggesting a possible cross resistance between enzalutamide and 
abiraterone are also retrospective with a limited number of patients [25], [26]. 
Clinical development of enzalutamide 
Before the use of enzalutamide in phase I–II studies, the effect of this drug was studied on 
CRPC xenograft models. Enzalutamide showed the ability to inhibit AR signalling in the 
overexpression of AR cells with high binding affinity to the AR and lack of agonist activity [18], 
[27]. Enzalutamide bound to the AR in a castration-resistant LNCaP/AR human prostate cancer 
cell model showing an eight-fold greater affinity than bicalutamide. Also, enzalutamide induced 
regression of established LMCaP/AR xenograft tumour cells, which overexpress ARs growing in 
castrated male mice [18], [27]. These data demonstrated the activity of enzalutamide and allowed 
the development of subsequent clinical studies. 
 
A phase I–II study was conducted by Scher et al. [28] to assess the antitumour activity and 
efficacy of enzalutamide in patients with progressive metastatic CRPC (mCRPC). In this study, 
140 patients were enrolled in dose-escalation cohorts of 3-6 patients starting with 30 mg dose. The 
final doses studies were 30 mg (n = 3), 60 mg (n = 27), 150 mg (n = 28), 240 mg (n = 29), 360 mg 
(n = 28), 480 mg (n = 22) and 600 mg (n = 3). Decreases in prostate specific antigen (PSA) levels 
were seen at all doses, in both chemotherapy-naïve and chemotherapy-treated patients, with a PSA 
decline of 50% or more in 56% of patients. Partial responses were observed in 13 (22%) out of 59 
patients with soft tissue metastases. The median time to radiological progression was 47 weeks. 
The maximum tolerated dose was 240 mg, with fatigue as the most frequent adverse event (grade 
3–4 in 11% of patients). The subsequent lower level (150 mg) was established as the dose to be 
used in further studies, although the final commercialised dose was 160 mg. This study also 
assessed AR binding in vivo in 22 patients using 16 beta[18F]-fluoro-5 alpha-dihydrotestosterone 
(FDHT) positron emission tomography (PET) scans to measure change in FDHT uptake before 
and after starting treatment. All patients showed a clear reduction in FDHT uptake (range 
approximately ∼20–100%). 
 
In the landmark phase III, double-blind, placebo-controlled AFFIRM (A Study Evaluating the 
Efficacy and Safety of the Investigational Drug MDV3100) trial [6], 1199 men with castration-
resistant prostate cancer with ⩽2 prior chemotherapy regimens, including ⩾1 containing 
docetaxel, were randomly assigned in a 2:1 ratio, to receive oral enzalutamide at a dose of 160 mg 
per day (800 patients) or placebo (399 patients). Corticosteroids administration was optional in 
both arms. At a planned interim analysis after 520 death events, enzalutamide was superior to 
placebo in the primary endpoint, overall survival (hazard ratio [HR] for death 0.63, 95% 
confidence interval [CI] 0.53–0.75, P < 0.001). On the basis of these results, an independent data 
and safety monitoring committee recommended that the study be halted and unblinded, with 
eligible patients in the placebo group offered treatment with enzalutamide. An additional analysis 
has been done based on data cut-off of 29-June-2012, when 734 events had been reported (61.2% 
of the total study population). Again, results remain in the same line: HR 0696 (95% CI: 0.599–
0.809) and a difference of 4.9 months in median time to death was observed. Enzalutamide was 
also superior over placebo with respect to all secondary endpoints, including reduction in PSA 
level by 50% or more (54% vs. 2%, P < 0.001); the soft-tissue response rate (29% vs. 4%, 
P < 0.001); the quality of life response rate (43% vs. 18%, P < 0.001); the time to PSA progression 
(8.3 vs. 3.0 months, HR 0.25, P < 0.001); radiographic progression-free survival (8.3 vs. 
2.9 months, HR 0.40, P < 0.001) and the time to the first skeletal-related event (16.7 vs. 
13.3 months, HR 0.69, P < 0.001). 
 
Enzalutamide has a good toxicity profile. The different target of enzalutamide and the lack of 
need to use concomitant steroids are likely to offer some potential advantages over abiraterone in 
terms of adverse events. In fact, a post hoc analysis of the AFFIRM trial found that on-study use of 
corticosteroids led to worse outcomes regardless of whether patients were randomly assigned to 
enzalutamide or placebo [29]. Median survival for on-study corticosteroid users was 12.8 months 
for the enzalutamide arm vs. 9.6 months for placebo (P < 0.001). For those not taking 
corticosteroids, the median survival was not yet reached in enzalutamide-treated patients vs. 
18.8 months for placebo (P < 0.001). The benefit of enzalutamide compared to placebo was seen 
in both corticosteroid- and non-corticosteroid-treated patients. Median progression-free survival 
for enzalutamide and placebo was 5.6 vs. 2.9 months, respectively, in on-study corticosteroid 
users, and 11.1 vs. 3 months in patients who did not use corticosteroids (P < 0.001 for both 
comparisons). Median time to PSA progression in on-study corticosteroid users was 5.6 months 
for enzalutamide and 3.1 months for placebo (P < 0.001) and 8.6 vs. 2.9 months, respectively 
(P < 0.001) among non-users. Use of on-study corticosteroids was associated with higher rates of 
grade 3 and 4 adverse events, including anaemia, fatigue, spinal cord compression and back pain. 
These results should be interpreted with caution, since this was a retrospective analysis, groups 
were not well balanced and the inferior outcomes in corticosteroid-treated patients may be due to 
unmeasured confounders or the biological properties of corticosteroid use itself. 
 
Abiraterone has also been tested in mCRPC patients with ECOG PS < 2 progression after 
docetaxel (phase III trial COU-AA-301) [4], [5]. Patients were randomized to either abiraterone 
plus prednisone or placebo plus prednisone. OS was increased with abiraterone treatment 
(15.8 months vs. 11.2 months; HR: 0.74; 95% CI: 0.64–0.86; P < 0.0001). Benefits were similar 
for all secondary endpoints. Several grade 3-4 toxicities were more frequent in patients treated 
with abiraterone, including fluid retention (4% vs. 1%), hypertension (1% vs. 0%) and cardiac 
disorders (4% vs. 2%). 
 
In the phase III PREVAIL study [30], enzalutamide was compared to placebo in the pre-
docetaxel setting. In a planned interim analysis, more than 1700 men with (mCRPC) that have 
progressed despite androgen deprivation therapy and chemotherapy naïve were analysed. Patients 
treated with enzalutamide demonstrated a statistically significant overall survival advantage 
compared with patients treated with placebo (P < 0.0001). Enzalutamide provided a 30% reduction 
in the risk of death compared with placebo (HR 0.70, 95% CI 0.59–0.83). Moreover, there was a 
statistically significant radiographic progression-free survival advantage compared with placebo-
treated patients (P < 0.0001) [30]. Enzalutamide provided an 81% reduction in the risk of 
radiographic progression or death versus placebo (HR 0.19, 95% CI 0.15–0.23). Also, patients on 
treatment with enzalutamide showed a delay of 17 months in time to initiation of subsequent as 
compared to patients treated with placebo (28.0 vs. 10.8 months, HR 0.35, P < 0.0001). A total of 
58.5% of enzalutamide-treated patients, most of them with soft tissue metastatic disease, showed 
complete or partial response as compared to 5% in placebo-treated patients. Before final database 
block, seizure events were not reported in the enzalutamide group as compared with one seizure 
event in the placebo group. A seizure event was notified in the enzalutamide group after database 
block and unblinding [30]. 
 
The efficacy of enzalutamide in three subsets of patients was assessed in subgroup analyses of 
the AFFIRM study, including elderly patients, patients with visceral metastases and long-term 
responders. In relation to elderly patients, older patients accounted for 25% (199/800) and 26% 
(104/399) of enzalutamide- and placebo-treated patients, respectively. Improved outcomes with 
enzalutamide treatment were observed in both elderly and younger patients, with similar safety 
profiles in each age group [31]. In patients ⩾75 years of age, the median overall survival was 
18.2 months in the enzalutamide arm as compared to 13.3 months in the placebo arm (HR 0.60, 
95% CI 0.43–0.86, P = 0.004). In patients <75 years, the median overall survival was not met 
(NM) for enzalutamide vs. 13.6 months for placebo (HR 0.63, 95% CI 0.52–0.78, P < 0.0001). 
Safety and tolerability data were comparable between the two age groups. 
  
In patients with visceral metastases [32], including liver metastases (11.5% [92/800] in the 
enzalutamide group and 8.5% [34/399] in the placebo group) and lung metastases (15.3% 
[122/800] in the enzalutamide group and 14.8% [59/399] in the placebo group), the median overall 
survival in patients with liver and/or lung metastatic disease was 11.4 months (enzalutamide 
13.4 months, placebo 9.5 months; HR 0.78 (95% CI 0.56–1.09). Improved outcomes with 
enzalutamide were observed in both liver and lung mCRPC patients. 
 
A total of 35% (276/800) of patients treated with enzalutamide were on therapy for >12 months 
and 22% (174/800) for >18 months [33]. When the long-term responder (LTR) subgroup was 
compared to the whole group of enzalutamide-treated patients, the median survival was longer (7.9 
vs. 5.9 years) and had lower disease burden at baseline. Also, 50% PSA response was 87% in the 
LTR subgroup and 54% in the whole enzalutamide group. 
 
Small clinical series of patients have been reported in which the clinical activity of abiraterone 
acetate was evaluated in mCRPC progressing after enzalutamide [25], [26] as well as the activity 
of enzalutamide in patients pre-treated with docetaxel and abiraterone [34], [35], [36], [37]. Data 
of these studies are summarised in Table 1. 
Table 1. Sequential treatment with enzalutamide and abiraterone in mCRPC. 
       
Baseline 
characteristics 
and outcome 
Abiraterone 
progressing 
after 
enzalutamide 
(reference #26) 
Abiraterone 
progressing after 
docetaxel and 
enzalutamide 
(reference #25) 
Enzalutamide 
progressing after 
docetaxel and 
abiraterone 
(reference #34) 
Enzalutamide 
progressing 
after abiraterone 
(reference #35) 
Enzalutamide 
progressing after 
docetaxel and 
abiraterone 
(reference #36) 
Enzalutamide 
progressing 
after abiraterone 
(reference #37) 
       
No. patients 30 38 35 20 39 23 
Age, years, 
median (range) 
70 (56–84) 71 (52–84) 70 (57–81) 76 (64–84) 70 (54–85) 76 (65–82) 
Metastatic sites 
(>1) 
26 (86.7) 37 (97.4) NR 13 (65) 33 (84.6) 22 (95.6) 
Bone 18 (60) 15 (39.5) NR 8 (40) 21 (53.8) NR 
Lymph nodes 9 (30) 10 (26.3) NR 4 (20) 6 (15.4) 4 (17.4) 
Efficacy 
endpoints 
      
PSA 
response ⩾ 50% 
1/27 (3.7)a 3/38 (7.9)a 10/35 (28.6)b 9/20 (45) 5/39 (12.8)a 9/23 (39.1) 
Overall survival, 
months 
      
Median (range) 11.5 (6.5–16.6) 7.2 (5.0-NYR) 7.1 (6.2–8.1)c NR NR NR 
Progression-free 
survival, months 
      
Median (95% CI) 3.5 (2.5–4.6) 2.7 (2.3–4.1) 4.0 (2.0–6.0) NR 2.8 (2.0–3.6) NR 
rProgression-free 
survival 
0 (0) 1/12 (8.3) 1/17 (5.9) NR NR 0 (0)d 
       
 
Abbreviations: NR: not reported; PSA: prostate-specific antigen; NYR: not yet reached; rProgression: radiographic 
progression. 
a PSA response defined as ⩾50% decline in PSA confirmed after ⩾4 weeks. 
b PSA response defined as >50% decline in PSA. 
c Overall survival calculated as mean. 
d A trend for improved radiographic progression-free survival in patients sensitive to abiraterone (15.7 vs. 11.4 weeks, 
P = 0.40). 
 
 
  
Toxicity of enzalutamide 
Enzalutamide has a favourable toxicity profile. In the phase I–II study [28], fatigue was the 
most common adverse effect, requiring dose reduction in 11% of patients treated with a daily dose 
of 240 mg or higher (grade 3). Fatigue usually appears after 30 days of treatment. Other grade 3–4 
toxicities were anaemia (3%) and joint pain (2%). Nausea, constipation, diarrhoea and anorexia 
were mild adverse effects. The percentage of patients who discontinued enzalutamide treatment 
was 13% in those treated with doses of 360 mg/day or higher, and 1% when the dose administered 
was 240 mg/day or lower. Two of the 140 patients included in the study developed seizures at 
doses of 360 and 600 mg/day, respectively; another patient possibly had seizures at a dose of 
480 mg/day. The two patients with seizures were also receiving concomitant medication that 
reduced the threshold for seizures. Other causes of treatment withdrawal were skin rash (2 
patients) and a myocardial infarction in a patient with a metabolic syndrome. 
 
In the phase III clinical trial [6], the rate of adverse events was similar in the enzalutamide and 
placebo arms, with a lower incidence of adverse events (grade < 3) in the enzalutamide group 
(45% vs. 53%) as compared with placebo. The time elapsed from starting treatment to the first 
adverse event was 12.6 months and 4.2 months in the enzalutamide and placebo groups, 
respectively. The incidence (any grade) of fatigue (34%), diarrhoea (21%), hot flashes (20%), 
musculoskeletal pain (14%) and headache (12%) was higher in the enzalutamide arm. Cardiac 
disorders were observed in 6% of patients and hypertension in 6.6% among enzalutamide-treated 
patients versus 8% and 3.3%, respectively, among placebo-treated patients. Patients remained on 
treatment for a median of 8.3 months in the enzalutamide group and 3 months in the placebo 
group. 
 
Of the 800 patients assigned to treatment with enzalutamide, seizures were recorded in 6 
patients (0.8%) (4 of the seizures were witnessed), whereas no seizures were reported in the 
placebo group. One of the five patients had a status epilepticus that required medical intervention; 
in the remaining cases, seizures events were self-limited and did not recur after discontinuation of 
treatment. However, potential predisposing factors were present in four patients (two patients had 
brain metastases, one patient had inadvertently been administered lidocaine intravenously 
immediately before seizure and one patient with brain atrophy had an unwitnessed event classified 
as a seizure). A mechanism of inhibition of the γ-aminobutyric acid (GABA) related to the ligand-
gated ion channels of the GABAA receptor complex, decreasing the threshold for seizures has been 
postulated [38]. For this reason, enzalutamide should be used with caution in patients with history 
of seizures or predisposing factors, such as brain injury, stroke, cerebral metastasis, alcoholism or 
patients concomitantly treated with medications that may reduce the threshold for seizures (such as 
droperidol, lidocaine, bupropion, insulin, lithium, etc.) and, in these cases, treatment should be 
stopped if seizures occur. There is an ongoing study to assess the safety of enzalutamide in 
patients at risk of seizure events. 
 
In the PREVAIL trial, incidence of hypertension and cardiac disorder in any grade were higher 
than in the AFFIRM study (13 vs. 6.6% and 10 vs. 6% respectively) [30], whereas the incidence of 
seizures happened less frequently in the PREVAIL trial (5 of 800 patients in AFFIRM, 1 of 871 
patients in PREVAIL). 
 
The most common adverse event recorded in three randomized clinical trials with the use of 
enzalutamide [6], abiraterone [4] and cabazitaxel [3] are shown in Table 2. 
  
Table 2. Adverse events recorded in three randomised studies of enzalutamide, abiraterone and cabazitaxel. 
      
Adverse event Enzalutamide (AFFIRM study, 
reference #6) 
 Abiraterone (COU.AA-301 
study, reference #4) 
 Cabazitaxel (TROPIC study, 
reference #3) 
Any grade Grade ⩾ 3  Any grade Grade ⩾ 3  Any grade Grade ⩾ 3 
         
Anaemia NR NR  23 7  97 11 
Thrombocytopaenia NR NR  4 1  47 4 
Febrile neutropenia NR NR  0 0  0 8 
Arthralgia NR NR  27 4  11 1 
Fatigue 34 6  44 8  37 5 
Headache 12 1  NR NR  NR NR 
Diarrhoea 21 1  18 1  47 6 
Cardiac disorder 6 1  13 4  NR  
Oedema/fluid retention NR NR  31 3  NR NR 
Hypertension 6.6   10 1  NR NR 
Nauseas NR NR  30 2  34 2 
Liver dysfunction 1 <1  10 3  NR NR 
Seizures <1 <1       
Urinary tract infection NR NR  12 2  7 1 
         
 
NR: not reported. 
Symptomatic benefit and enzalutamide 
Secondary endpoints in the trials of enzalutamide included improvement in health-related 
quality of life, relief of pain and time to the first skeletal-related event. Improvement of the quality 
of life is a very relevant objective in the treatment of patients with mCRPC. The Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire is a reliable self-administrated 
scale for assessing health-related quality of life in patients with prostate cancer [40]. The FACT-P 
is a 39-item questionnaire on which the score for each item can range from 0 to 4, with higher 
scores indicating a better quality of life. 
 
In the pivotal randomised trial of enzalutamide [6], quality-of-life response (a secondary 
endpoint) was defined as a 10-point improvement in the global score on the FACT-P 
questionnaire, as compared with baseline, on two consecutive measurements obtained at least 
3 weeks apart, and worsening as 10-point decrease. Patients with baseline and ⩾1 post-baseline 
evaluation were included in the analysis (n = 938) [41]. A greater percentage of patients on 
enzalutamide reported health-related quality of life improvement compared to placebo (42.2% vs. 
14.5%, P < 0.001), with a median time to the first quality of life deterioration of 9.0 and 
3.7 months for enzalutamide and placebo, respectively (P < 0.001). Overall, 46.8% of patients on 
enzalutamide and 59.3% on placebo experienced health-related quality of life deterioration at some 
point while on treatment (P = 0.001). The time to the first skeletal-related event (defined as 
pathological fracture, spinal cord compression or palliative radiation therapy or surgery to bone) 
was 16.7 vs. 13.3 months for the arms of enzalutamide and placebo, respectively (HR 0.69, 
P < 0.001). 
 
In the AFFIRM trial [6], patients were stratified according to the baseline Eastern Cooperative 
Oncology Group (ECOG) performance status score and the Brief Pain Inventory-Short Form (BPI-
SF) question 3 score addressing the average pain over the 7 days before randomisation (0–3 [no 
pain to mild pain] vs. 4–10 [moderate-to-severe pain]). At baseline, 28% had a BPI-SF score ⩾4. 
Palliation of pain was defined as a decrease of ⩾30% in the BPI-SF score on week 13 as compared 
to baseline, without an increase ⩾30% in the use of analgesics. Palliation of pain was achieved by 
45% of enzalutamide patients vs. 7% of placebo patients (P = 0.0079). Pain progression was 
recorded in 28% of patients treated with enzalutamide and in 39% of patients treated with placebo 
(P = 0.0018) [42]. 
 
In the COU-AA-301 randomised trial [39], secondary endpoints were pain control and skeletal-
related events. Pain intensity defined as item 3 of the BPI-SF in the past 24 hours. Patients with 
BPI-SF score ⩾4 at baseline were included in the analysis. Pain intensity palliation was defined 
according two consecutive follow-up visits (at least 4 weeks apart) at which the pain intensity 
score was at least 30% lower than that at baseline, without an increase in analgesic use (defined as 
a ⩾1 point increase on the WHO analgesic scale). Abiraterone acetate plus prednisone resulted in 
significantly more pain palliation than prednisone (45% vs. 28.8%, P = 0.0005). The median time 
to occurrence of first skeletal-event was also longer with abiraterone (25 vs. 20.3 months, 
P = 0.0001). In a recent analysis [43], significant improvements in the FACT-P total score were 
observed in 48% of patients receiving abiraterone acetate plus prednisone vs. 32% of patients 
receiving prednisone (P < 0.0001). 
 
In the prednisone plus cabazitaxel or mitoxantrone for mCRPC (TROPIC study) [3], pain and 
analgesic was assessed with the McGill-Melzack present pain intensity (PPI) scale and analgesic 
use was derived from consumption normalised to morphine equivalents. Pain response rates were 
similar in the two groups (7.7% mitoxantrone vs. 9.2% cabazitaxel, P = 0.63). 
Future directions 
New questions currently arise in the context of androgen deprivation therapy and AR-
dependent tumours. Which is the best drug for starting treatment? Which drug combination 
improves efficacy or reverses resistance to other treatments? Is enzalutamide active in patients 
with other solid tumours? According to recent favourable results of enzalutamide obtained in the 
phase III PREVAIL study [30], enzalutamide is an option in the treatment of mCRPC before 
docetaxel. However, final analyses of the PREVAIL trial and data provided by other ongoing 
studies will contribute to define the better use of enzalutamide and other drugs in mCRPC. 
 
At the present time, other studies of enzalutamide in the pre-chemotherapy setting have been 
registered, such as enzalutamide versus bicalutamide in castrate men with metastatic prostate 
cancer who have progressed while on while on luteinizing hormone receptor hormone (LHRH) 
agonist/antagonist or after receiving a bilateral orchiectomy (NCT01288911). This ongoing, head-
to-head, phase 2 clinical trial (TERRAIN study) [44] is the first to prospectively determine 
whether enzalutamide can provide improved antitumour effects vs. bicalutamide in men with 
metastatic progressive CRPC (enrollment 375 patients). Enzalutamide vs. bicalutamide in men 
with prostate cancer who have failed after primary androgen deprivation therapy is also being 
evaluated in a phase II study (STRIVE), in which both metastatic and non-metastatic patients are 
eligible (enrollment 400 patients) (NCT01664923). Also, enzalutamide as neoadjuvant therapy is 
being assessed in combination with LHRH analogues (leuprolide and dutasteride) (NCT01547299) 
or with of abiraterone acetate and prednisone (NCT01946165, NCT01949337). In bone mCRPC, 
the combination of enzalutamide and abiraterone is going to be assessed in a phase II study 
(NCT01650194) as well as the combination of enzalutamide and docetaxel in advanced prostate 
cancer in a phase I study (NCT01565928). 
 
In other hand, enzalutamide is being tested in combination phase I trials for metastatic 
castration-resistant prostate cancer patients with everolimus (NTC02125084) and crizotinib 
(NTC02207504). In phase II trials combining with tivozanib (NTC01885949), sipuleucel T 
(NTC01981122), Radium 223 (NTC02199197 and NTC02225704) or even PSA-TRICOM 
vaccine in combination with enzalutamide (NTC01875230). Interestingly, there is a phase II trial 
comparing Radium 223 alone against Radium 223 with abiraterone acetate or Radium 223 with 
enzalutamide in metastatic castration-resistant prostate cancer patients (NTC02034552). In some 
phase III trials other combinations are being tested, such as in the PEACE III trial, where 
enzalutamide alone is compared with enzalutamide with Radium 223 (NTC02194842) and the arm 
J in the STAMPEDE trial where they test the combination of antiandrogens deprivation therapy 
plus abiraterone acetate plus enzalutamide and prednisolone (NTC00268476). 
 
Enzalutamide is also being studied in other tumours, such as in patients with advanced, 
androgen receptor-positive, triple negative breast cancer (NCT01889238) and in a phase I study of 
patients with incurable breast cancer (NCT01597193). A summary of these studies is shown in 
Table 3. 
Table 3. Summary of registered clinical trials of enzalutamide in ClinicalTrials.gov. 
    
ClinicalTrials.gov 
identifier 
Study Treatment arms Comments 
    
NCT0121299 Phase 
III 
A: enzalutamide Pre-chemotherapy 
B: placebo 
NCT01288911 Phase 
II 
A: enzalutamide After LHRH analogue or bilateral surgical 
orchiectomy B: bicalutamide 
NCT01547299 Phase 
II 
A: enzalutamide Neoadjuvant 
B: enzalutamide–leuprolide–dutasteride 
NCT01946165 Phase 
II 
A: abiraterone–LHRH analogue Neoadjuvant 
B: enzalutamide–abiraterone–LHRH 
analogue 
NCT01949337 Phase 
III 
A: enzalutamide Post-chemotherapy 
B: enzalutamide–abiraterone 
NCT01650194 Phase 
II 
Enzalutamide–abiraterone Pre-chemotherapy 
NCT01565928 Phase I Enzalutamide–docetaxel mCRPC 
NTC02125084 Phase I Enzalutamide–everolimus mCRPC 
NTC02207504 Phase I Enzalutamide–crizotinib mCRPC 
NTC01885949 Phase 
II 
Enzalutamide–tivozanib mCRPC 
NTC01981122 Phase 
II 
Enzalutamide–sipuleucel T mCRPC 
NTC02034552 Phase 
II 
A: Radium 223 mCRPC 
B: Radium 223–enzalutamide 
C: Radium 223–abiraterone 
NTC01875230 Phase 
II 
A: Enzalutamide mCRPC 
B: Enzalutamide–PSA-TRICOM 
NTC02194842 Phase 
III 
A: Enzalutamide mCRPC 
B: Enzalutamide–Radium 223 
NTC00268476 Phase 
III 
Antiandrogen deprivation therpy–
Enzalutamide–abiraterone 
Arm J, STAMPEDE trial 
NTC02138383 Phase I Enzalutamide–nab-paclitaxel–gemcitabine Pancreatic cancer 
NCT01889238 Phase 
II 
Enzalutamide Triple negative breast cancer, androgen 
receptor-positive 
NCT01597193 Phase I Enzalutamide Incurable breast cáncer 
    
 
 
 
  
Concluding remarks 
The AR signalling pathway is a crucial element in the natural history of mCRPC. Four drugs 
have been approved for this indication and are currently available for the treatment of patients with 
mCRPC progressing after docetaxel therapy: enzalutamide, abiraterone, cabazitaxel and RAD-223. 
The anti-tumour activity of the first three drugs is explained, at least in part, by the mechanism of 
action on the androgenic signalling pathway at the AR or the androgen precursors level. 
Enzalutamide has a much higher binding affinity to the AR than the other anti-androgenic drugs, 
and is without agonist properties. In contrast to abiraterone, enzalutamide acts through ligand-
dependent and independent resistance mechanisms. Enzalutamide also lacks the detrimental effects 
of mineralocorticoid excess, so contrary to what occurs with abiraterone, concomitant 
administration of systemic corticosteroids is not needed. Health-related quality of life is an 
important goal in the treatment of an incurable disease such as mCRPC, so that the best treatment 
is probably that which allowing control of the disease together with a better and more effective 
control of symptoms with fewer adverse effects. In this respect, although measurements of quality 
of life cannot be extrapolated across different studies, results reported support that treatment of 
mCRPC has clinical benefits for the patient. In relation to drug-related adverse events, abiraterone 
and enzalutamide appear to be better tolerated, with the difference that in the case of enzalutamide, 
concurrent administration of corticosteroids is not necessary, so it does have the risk of 
corticosteroids-related complications. Finally, it should be pointed out that because of its 
mechanism of action, good tolerance and results of the PREVAIL study [30], several studies are 
being conducted aimed at positioning enzalutamide in other phases of the clinical evolution of 
mCRPC, as well as defining its role in combination with other active drugs for the treatment of 
this neoplasm. 
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